000126346 001__ 126346
000126346 005__ 20230602105037.0
000126346 0247_ $$2doi$$a10.3390/bioengineering10050572
000126346 0248_ $$2sideral$$a133772
000126346 037__ $$aART-2023-133772
000126346 041__ $$aeng
000126346 100__ $$aMármol, Inés
000126346 245__ $$aTowards novel biomimetic in vitro models of the blood-brain barrier for drug permeability evaluation
000126346 260__ $$c2023
000126346 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126346 5203_ $$aCurrent available animal and in vitro cell-based models for studying brain-related pathologies and drug evaluation face several limitations since they are unable to reproduce the unique architecture and physiology of the human blood–brain barrier. Because of that, promising preclinical drug candidates often fail in clinical trials due to their inability to penetrate the blood–brain barrier (BBB). Therefore, novel models that allow us to successfully predict drug permeability through the BBB would accelerate the implementation of much-needed therapies for glioblastoma, Alzheimer’s disease, and further disorders. In line with this, organ-on-chip models of the BBB are an interesting alternative to traditional models. These microfluidic models provide the necessary support to recreate the architecture of the BBB and mimic the fluidic conditions of the cerebral microvasculature. Herein, the most recent advances in organ-on-chip models for the BBB are reviewed, focusing on their potential to provide robust and reliable data regarding drug candidate ability to reach the brain parenchyma. We point out recent achievements and challenges to overcome in order to advance in more biomimetic in vitro experimental models based on OOO technology. The minimum requirements that should be met to be considered biomimetic (cellular types, fluid flow, and tissular architecture), and consequently, a solid alternative to in vitro traditional models or animals.
000126346 536__ $$9info:eu-repo/grantAgreement/EC/H2020/778354/EU/Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine/CISTEM$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 778354-CISTEM$$9info:eu-repo/grantAgreement/EC/H2020/829010/EU/Advanced and versatile PRInting platform for the next generation of active Microfluidic dEvices/PRIME$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 829010-PRIME$$9info:eu-repo/grantAgreement/EC/H2020/876190/EU/Accelerating Innovation in Microfabricated Medical Devices/Moore4Medical$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 876190-Moore4Medical$$9info:eu-repo/grantAgreement/ES/MICINN/Juan de la Cierva Program-FJC-2021-047401-I$$9info:eu-repo/grantAgreement/ES/MINECO/DIN2020-011544
000126346 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126346 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000126346 700__ $$0(orcid)0000-0002-5954-7786$$aAbizanda-Campo, Sara
000126346 700__ $$aAyuso, José M.
000126346 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, Ignacio$$uUniversidad de Zaragoza
000126346 700__ $$0(orcid)0000-0003-0156-4230$$aOliván, Sara$$uUniversidad de Zaragoza
000126346 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000126346 773__ $$g10, 5 (2023), 572 [22 pp.]$$pBioengineering$$tBioengineering$$x2306-5354
000126346 8564_ $$s3506714$$uhttps://zaguan.unizar.es/record/126346/files/texto_completo.pdf$$yVersión publicada
000126346 8564_ $$s2761401$$uhttps://zaguan.unizar.es/record/126346/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126346 909CO $$ooai:zaguan.unizar.es:126346$$particulos$$pdriver
000126346 951__ $$a2023-06-02-09:10:16
000126346 980__ $$aARTICLE